Immune-checkpoint blockade treatments, particularly drugs inhibiting programmed death-ligand 1 (PD-L1) with its receptor, programmed cell death protein-1 (PD-1) has demonstrated promising clinical efficacy in patients with advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.